Abstract
Preparations of the Cannabis sativa plant have been used to analgesic effect for millenia, but only in recent decades has the endogenous system responsible for these effects been described. The endocannabinoid (EC) system is now known to be one of the key endogenous systems regulating pain sensation, with modulatory actions at all stages of pain processing pathways. The EC system is composed of two main cannabinoid receptors (CB1 and CB2) and two main classes of endogenous ligands or endocannabinoids (ECs). The receptors have distinct expression profiles, with CB1 receptors found at presynaptic sites throughout the peripheral and central nervous systems (PNS and CNS, respectively), whilst CB2 receptor is found principally (but not exclusively) on immune cells. The endocannabinoid ligands are lipid neurotransmitters belonging to either the N-acyl ethanolamine (NAEs) class, e.g. anandamide (AEA), or the monoacylglycerol class, e.g. 2-arachidonoyl glycerol (2-AG). Both classes are short-acting transmitter substances, being synthesised on demand and with signalling rapidly terminated by specific enzymes. ECs acting at CB1 negatively regulate neurotransmission throughout the nervous system, whilst those acting at CB2 regulate the activity of CNS immune cells. Signalling through both of these receptor subtypes has a role in normal nociceptive processing and also in the development resolution of acute pain states. In this chapter, we describe the general features of the EC system as related to pain and nociception and discuss the wealth of preclinical and clinical data involving targeting the EC system with focus on two areas of particular promise: modulation of 2-AG signalling via specific enzyme inhibitors and the role of spinal CB2 in chronic pain states.
Keywords
- Pain
- Endocannabinoid
- Analgesia
This is a preview of subscription content, access via your institution.
Buying options

Abbreviations
- 2-AG:
-
2-Arachidonoyl glycerol
- Δ9-THC:
-
Δ9-Tetrahydrocannabinol
- ABHD6:
-
αβ-Hydrolase domain 6
- ABHD12:
-
αβ-Hydrolase domain 12
- ACC:
-
Anterior cingulate cortex
- AEA:
-
Anandamide
- AM251:
-
A CB1 selective receptor inverse agonist/antagonist
- CB1 :
-
Cannabinoid type 1 receptor
- CB2 :
-
Cannabinoid type 2 receptor
- CCI:
-
Chronic constriction injury (neuropathic pain model)
- CNS:
-
Central nervous system
- DAGLα:
-
Diacylglycerol lipase-α
- DRG:
-
Dorsal root ganglia
- EC:
-
Endocannabinoid
- FAAH:
-
Fatty acid amide hydrolase
- fMRI:
-
Functional magnetic resonance imaging
- GPCR:
-
G protein-coupled receptor
- MAG:
-
Monoacylglycerol
- MAGL:
-
Monoacylglycerol lipase
- NAE:
-
N-acylethanolamine
- NAPE-PLD:
-
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D
- PAG:
-
Periaqueductal grey matter
- PKC:
-
Protein kinase C
- PNS:
-
Peripheral nervous system
- RVM:
-
Rostral ventromedial medulla
- SR144528:
-
A CB2 selective receptor antagonist
- TRPV1:
-
Transient receptor potential vanilloid 1
- WDR:
-
Wide dynamic range neuron; a class of spinal neuron with key involvement in the transduction of nociceptive input
References
Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614
Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870–879
Aguiar DC, Moreira FA, Terzian AL, Fogaca MV, Lisboa SF, Wotjak CT, Guimaraes FS (2014) Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels. Neurosci Biobehav Rev 46(Pt 3):418–428
Alexander SPH, Kendall DA (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152:602–623
Alkaitis MS, Solorzano C, Landry RP, Piomelli D, Deleo JA, Romero-Sandoval EA (2010) Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One 5:e10891
Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467–479
Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS (2000) Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396:85–92
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. J Cell Biol 163:463–468
Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, Razdan RK, Wiley JL, Di Marzo V (2009) Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4:946–950
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347–1356
Brownjohn PW, Ashton JC (2012) Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience 203:180–193
Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng W-S, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104:9800–9805
Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V (2013) Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 8:e80440
Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479–486
Cabral GA, Griffin-Thomas L (2009) Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11:e3
Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251
Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5:e8688
Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, Piesla MJ, Zhang M-Y, Bingham B, Uveges A, Kowal D, Garbe D, Kouranova EV, Ring RH, Bates B, Pangalos MN, Kennedy JD, Whiteside GT, Samad TA (2010) Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 78:996–1003
Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102–113
Chapman V (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127:1765–1767
Chen FL, Dong YL, Zhang ZJ, Cao DL, Xu J, Hui J, Zhu L, Gao YJ (2012) Activation of astrocytes in the anterior cingulate cortex contributes to the affective component of pain in an inflammatory pain model. Brain Res Bull 87:60–66
Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13:6
D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D (2009) Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 613:54–59
Desroches J, Guindon J, Lambert C, Beaulieu P (2008) Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155:913–924
Desroches J, Bouchard JF, Gendron L, Beaulieu P (2014a) Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 261:23–42
Desroches J, Charron S, Bouchard JF, Beaulieu P (2014b) Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB(1) and CB(2) receptors. Neuropharmacology 77:441–452
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol 34:605–613
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
Di Marzo V, De Petrocellis L (2012) Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 367:3216–3228
Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686–691
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99:10819–10824
Doğrul A, Gül H, Yildiz O, Bilgin F, Güzeldemir ME (2004) Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368:82–86
Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol 422:159–171
Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352–358
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83(3):1017–1066
Garcia-Merino A (2013) Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 13:9–13
Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, Lichtman AH (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92:498–505
Glaser ST, Kaczocha M (2010) Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J Pharmacol Exp Ther 335:380–388
Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M (2010) Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 23:25–34
Gregg LC, Jung K-M, Spradley JM, Nyilas R, Suplita RL, Zimmer A, Watanabe M, Mackie K, Katona IN, Piomelli D, Hohmann AG (2012) Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci 32:9457–9468
Guindon J, Beaulieu P (2006) Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50:814–823
Guindon J, Loverme J, De Lean A, Piomelli D, Beaulieu P (2006) Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol 550:68–77
Guindon J, Desroches J, Beaulieu P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150:693–701
Guindon J, Guijarro A, Piomelli D, Hohmann AG (2011) Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163:1464–1478
Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67:94–109
Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611–1616
Han KH, Lim S, Ryu J, Lee CW, Kim Y, Kang JH, Kang SS, Ahn YK, Park CS, Kim JJ (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 84:378–386
Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J, Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G, Zhang X (2012) Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148:1039–1050
Hao M-X, Jiang L-S, Fang N-Y, Pu J, Hu L-H, Shen L-H, Song W, He B (2010) The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J Lipid Res 51:2181–2190
Hegyi Z, Kis G, Holló K, Ledent C, Antal M (2009) Neuronal and glial localization of the cannabinoid-1 receptor in the superficial spinal dorsal horn of the rodent spinal cord. Eur J Neurosci 30:251–262
Hegyi Z, Holló K, Kis G, Mackie K, Antal M (2012) Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. Glia 60(9):1316–1329
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, Decosta BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936
Herkenham M, Lynn AB, Johnson MR, Melvin LS, Decosta BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat-brain—a quantitative in vitro autoradiographic study. J Neurosci 11:563–583
Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112
Horvath E, Woodhams SG, Nyilas R, Henstridge CM, Kano M, Sakimura K, Watanabe M, Katona I (2014) Heterogeneous presynaptic distribution of monoacylglycerol lipase, a multipotent regulator of nociceptive circuits in the mouse spinal cord. Eur J Neurosci 39:419–434
Hu JH, Yang L, Kammermeier PJ, Moore CG, Brakeman PR, Tu J, Yu S, Petralia RS, Li Z, Zhang PW, Park JM, Dong X, Xiao B, Worley PF (2012) Preso1 dynamically regulates group I metabotropic glutamate receptors. Nat Neurosci 15:836–844
Hu SS-J, Ho Y-C, Chiou L-C (2014) No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids. Eur J Neurosci 39:467–484
Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153:1837–1846
Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093–3098
Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP (2006) CB2 cannabinoid receptor mediation of antinociception. Pain 122:36–42
Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, Tao Q, O’Neal ST, Walentiny DM, Wiley JL, Cravatt BF, Lichtman AH (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171(6):1392–1407
Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281–288
Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26:13318–13327
Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SPH, Kendall DA, Barrett DA, Chapman V (2008) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55:85–93
Kaplan BLF (2013) The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 137:365–374
Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81
Katona I, Freund T (2012) Multiple functions of endocannabinoid signalling in the brain. Annu Rev Neurosci 35:529–558
Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544–4558
Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS (2011) Increasing 2-arachidonoyl glycerol signalling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 64:60–67
Kinsey SG, Long JZ, O’Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902–910
Kinsey SG, Long JZ, Cravatt BF, Lichtman AH (2010) Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11:1420–1428
Kinsey SG, Nomura DK, O’Neal ST, Long JZ, Mahadevan A, Cravatt BF, Grider JR, Lichtman AH (2011) Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338:795–802
Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH (2013) Repeated low dose administration of the monoacylglycerol lipase inhibitor JZL184 retains CB1 receptor mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345(3):492–501
La Porta C, Bura SA, Aracil-Fernandez A, Manzanares J, Maldonado R (2013) Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. Pain 154:160–174
Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134
Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720–4726
Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585–593
Lichtman A, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt B (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448
Lim G, Sung B, Ji RR, Mao J (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105:275–283
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19
Long JZ, Li WW, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF (2009a) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37–44
Long JZ, Nomura DK, Cravatt BF (2009b) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16:744–753
Lu Y, Zhu L, Gao YJ (2011) Pain-related aversion induces astrocytic reaction and proinflammatory cytokine expression in the anterior cingulate cortex in rats. Brain Res Bull 84:178–182
Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P (1996) Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci 8:1488–1500
Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, De Novellis V, Malcangio M, Maione S (2010) 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyraz ole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis 37:177–185
Maione S, Bisogno T, De Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316:969–982
Maione S, De Petrocellis L, De Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766–781
Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM (1995) An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56:2103–2109
Martin WJ, Hohmann AG, Walker JM (1996) Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16:6601–6611
Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237–242
Mechoulam R, Gaoni Y (1967) Absolute configuration of delta1-tetrahydrocannabinol major active constituent of hashish. Tetrahedron Lett 12:1109–1111
Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21–47
Meng ID, Johansen JP (2004) Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124:685–693
Min R, Nevian T (2012) Astrocyte signalling controls spike timing-dependent depression at neocortical synapses. Nat Neurosci 15:746–753
Nadal X, La Porta C, Andreea Bura S, Maldonadois R (2013) Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol 716(1–3):142
Navarrete M, Araque A (2008) Endocannabinoids mediate neuron-astrocyte communication. Neuron 57:883–893
Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I (2009) Molecular architecture of endocannabinoid signalling at nociceptive synapses mediating analgesia. Eur J Neurosci 29:1964–1978
Nyíri G, Cserép C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–822
Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729–738
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305
Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, Barrett DA, Kendall DA, Bennett AJ, Chapman V (2012) Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol 167:627–640
Pacher P, Mechoulam R (2011) Is lipid signalling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193–211
Pattij T, Wiskerke J, Schoffelmeer ANM (2008) Cannabinoid modulation of executive functions. Eur J Pharmacol 585:458–463
Pernia-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, Filitz J, Koppert W, Schuttler J, Ji G, Neugebauer V, Marsicano G, Lutz B, Vanegas H, Zeilhofer HU (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325:760–764
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
Petrosino S, Palazzo E, De Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415–422
Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955–960
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Bellora N (2008a) Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signalling during neuropathic pain. J Neurosci 28:12136–12145
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Manzanares J, Zimmer A, Maldonado R (2008b) Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28:12125–12135
Radulovic J, Tronson NC (2012) Preso1, mGluR5 and the machinery of pain. Nat Neurosci 15:805–807
Rahn EJ, Makriyannis A, Hohmann AG (2007) Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152:765–777
Rea K, Roche M, Finn DP (2007) Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152:633–648
Rea K, Olango WM, Okine BN, Madasu MK, Mcguire IC, Coyle K, Harhen B, Roche M, Finn DP (2014) Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 155:69–79
Richardson JD, Aanonsen L, Hargreaves KM (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3–R4
Romero-Sandoval A, Chai N, Nutile-Mcmenemy N, Deleo JA (2008a) A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 1219:116–126
Romero-Sandoval A, Nutile-Mcmenemy N, Deleo JA (2008b) Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108:722–734
Romero-Sandoval EA, Horvath R, Landry RP, Deleo JA (2009) Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 5:25
Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790–801
Russo R, Loverme J, La Rana G, Compton TR, Parrott JA, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236–242
Sagar DR, Kelly S, Millns PJ, O’Shaughnessey CT, Kendall DA, Chapman V (2005) Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22:371–379
Sagar DR, Kendall DA, Chapman V (2008) Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155(8):1297–1306
Sagar DR, Jhaveri M, Richardson D, Gray RA, De Lago E, Fernandez-Ruiz J, Barrett D, Kendall D, Chapman V (2010a) Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. Eur J Neurosci 31:8
Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SPH, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V (2010b) Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 62:3666–3676
Sagar DR, Burston JJ, Woodhams SG, Chapman V (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 367:3300–3311
Salio C, Fischer J, Franzoni MF, Conrath M (2002) Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience 110:755–764
Samson MT, Small-Howard A, Shimoda LMN, Koblan-Huberson M, Stokes AJ, Turner H (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170:4953–4962
Sang N, Zhang J, Chen C (2006) PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 572:735–745
Sang N, Zhang J, Chen C (2007) COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 102:1966–1977
Savinainen JR, Saario SM, Laitinen JT (2011) The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol 204:267–276
Schlosburg J, Carlson B, Ramesh D, Abdullah R, Long J, Cravatt B, Lichtman A (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11:342–352
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu Q-S, Lichtman AH, Cravatt BF (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113–1119
Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/β-hydrolase 4 in this pathway. J Biol Chem 281:26465–26472
Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283:9341–9349
Spradley JM, Guindon J, Hohmann AG (2010) Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62:249–258
Stander S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38:177–188
Starowicz K, Przewlocka B (2012) Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci 367:3286–3299
Stella N (2004) Cannabinoid signalling in glial cells. Glia 48:267–277
Stella N (2009) Endocannabinoid signalling in microglial cells. Neuropharmacology 56(Suppl 1):244–253
Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017–1030
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773–778
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605–612
Suplita RL, Farthing JN, Gutierrez T, Hohmann AG (2005) Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49:1201–1209
Suplita RL, Gutierrez T, Fegley D, Piomelli D, Hohmann AG (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50:372–379
Todd AJ (2010) Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 11:823–836
Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280(9):1874–1894
Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I (2004) The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371:167–170
Vachon-Presseau E, Martel M-O, Roy M, Caron E, Albouy GV, Marin M-F, Plante I, Sullivan MJ, Lupien SJ, Rainville P (2013) Acute stress contributes to individual differences in pain and pain-related brain activity in healthy and chronic pain patients. J Neurosci 33:6826–6833
Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ (2007) Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150:186–191
Vaughan CW, Mcgregor IS, Christie MJ (1999) Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127:935–940
Vaughan CW, Connor M, Bagley EE, Christie MJ (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57:288–295
Velazquez KT, Mohammad H, Sweitzer SM (2007) Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 55:578–589
Walker M, Huang S (2002) Cannabinoid analgesia. Pharmacol Ther 95:127–135
Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96:12198–12203
Walter L, Franklin A, Witting A, Wade C, Xie YH, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398–1405
Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10–18
Welch SP, Dunlow LD, Patrick GS, Razdan RK (1995) Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J Pharmacol Exp Ther 273:1235–1244
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592
Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46
Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SPH (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167:1609–1619
Yamamoto W, Mikami T, Iwamura H (2008) Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583:56–61
Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O’Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17:2750–2754
Zhang F, Hong S, Stone V, Smith PJW (2007) Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 323:508–515
Zygmunt PM, Petersson J, Andersson DA, Chuang HH, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457
Acknowledgements
D.S. and J.J.B. are funded by Arthritis Research UK Pain Centre funding (grant no. 18769).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Woodhams, S.G., Sagar, D.R., Burston, J.J., Chapman, V. (2015). The Role of the Endocannabinoid System in Pain. In: Schaible, HG. (eds) Pain Control. Handbook of Experimental Pharmacology, vol 227. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46450-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-662-46450-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46449-6
Online ISBN: 978-3-662-46450-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)